Invivyd (IVVD) Competitors $0.72 +0.00 (+0.25%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$0.77 +0.05 (+6.22%) As of 04:45 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IVVD vs. TERN, HUMA, PRTA, HRTX, AMRN, PRME, SNDL, AQST, CTOR, and OLMAShould you be buying Invivyd stock or one of its competitors? The main competitors of Invivyd include Terns Pharmaceuticals (TERN), Humacyte (HUMA), Prothena (PRTA), Heron Therapeutics (HRTX), Amarin (AMRN), Prime Medicine (PRME), SNDL (SNDL), Aquestive Therapeutics (AQST), Citius Oncology (CTOR), and Olema Pharmaceuticals (OLMA). These companies are all part of the "pharmaceutical products" industry. Invivyd vs. Its Competitors Terns Pharmaceuticals Humacyte Prothena Heron Therapeutics Amarin Prime Medicine SNDL Aquestive Therapeutics Citius Oncology Olema Pharmaceuticals Terns Pharmaceuticals (NASDAQ:TERN) and Invivyd (NASDAQ:IVVD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, institutional ownership, valuation, risk, analyst recommendations and earnings. Does the media refer more to TERN or IVVD? In the previous week, Invivyd had 5 more articles in the media than Terns Pharmaceuticals. MarketBeat recorded 8 mentions for Invivyd and 3 mentions for Terns Pharmaceuticals. Terns Pharmaceuticals' average media sentiment score of 1.34 beat Invivyd's score of 0.71 indicating that Terns Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Terns Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Invivyd 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in TERN or IVVD? 98.3% of Terns Pharmaceuticals shares are held by institutional investors. Comparatively, 70.4% of Invivyd shares are held by institutional investors. 1.5% of Terns Pharmaceuticals shares are held by company insiders. Comparatively, 25.4% of Invivyd shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is TERN or IVVD more profitable? Terns Pharmaceuticals has a net margin of 0.00% compared to Invivyd's net margin of -389.01%. Terns Pharmaceuticals' return on equity of -28.81% beat Invivyd's return on equity.Company Net Margins Return on Equity Return on Assets Terns PharmaceuticalsN/A -28.81% -27.55% Invivyd -389.01%-165.24%-99.71% Do analysts recommend TERN or IVVD? Terns Pharmaceuticals presently has a consensus price target of $15.63, indicating a potential upside of 266.78%. Invivyd has a consensus price target of $5.85, indicating a potential upside of 709.13%. Given Invivyd's stronger consensus rating and higher possible upside, analysts plainly believe Invivyd is more favorable than Terns Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Terns Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60Invivyd 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Which has more risk & volatility, TERN or IVVD? Terns Pharmaceuticals has a beta of -0.11, indicating that its stock price is 111% less volatile than the S&P 500. Comparatively, Invivyd has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Which has preferable earnings and valuation, TERN or IVVD? Terns Pharmaceuticals has higher earnings, but lower revenue than Invivyd. Terns Pharmaceuticals is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTerns PharmaceuticalsN/AN/A-$88.85M-$1.09-3.91Invivyd$25.38M3.42-$169.93M-$1.20-0.60 SummaryInvivyd beats Terns Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Get Invivyd News Delivered to You Automatically Sign up to receive the latest news and ratings for IVVD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IVVD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IVVD vs. The Competition Export to ExcelMetricInvivydMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$86.52M$2.88B$5.54B$8.87BDividend YieldN/A2.64%5.39%4.10%P/E Ratio-0.6021.3126.1719.90Price / Sales3.42278.47413.55113.66Price / CashN/A41.4736.1356.90Price / Book1.297.518.025.38Net Income-$169.93M-$55.05M$3.15B$248.50M7 Day Performance-9.50%2.07%1.48%2.06%1 Month Performance-25.18%4.84%3.66%4.86%1 Year Performance-34.27%5.37%34.68%20.24% Invivyd Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IVVDInvivyd3.274 of 5 stars$0.72+0.2%$5.85+709.1%-34.3%$86.52M$25.38M-0.60100News CoverageGap UpTERNTerns Pharmaceuticals4.0978 of 5 stars$3.73-2.6%$15.63+318.9%-36.6%$334.50MN/A0.0040HUMAHumacyte2.6878 of 5 stars$2.09-1.4%$11.71+460.5%-54.8%$328.85M$1.57M0.00150PRTAProthena3.2049 of 5 stars$6.07-0.2%$31.50+418.9%-69.0%$327.27M$135.16M-2.92130HRTXHeron Therapeutics3.9416 of 5 stars$2.07-3.3%$5.00+141.5%-21.5%$326.49M$144.29M-34.50300Positive NewsAMRNAmarin0.7503 of 5 stars$16.22+3.2%$12.00-26.0%+18.1%$325.31M$228.61M-4.46360High Trading VolumePRMEPrime Medicine3.5781 of 5 stars$2.47+2.1%$10.08+308.2%-41.9%$324.30M$3.85M-1.20234High Trading VolumeSNDLSNDL3.9501 of 5 stars$1.21-1.6%$3.63+199.6%-33.5%$323.21M$671.81M0.002,516Positive NewsAQSTAquestive Therapeutics1.4074 of 5 stars$3.31+1.8%$10.14+206.4%+52.1%$322.82M$57.56M-5.61160News CoverageCTORCitius Oncology0.3667 of 5 stars$4.35-3.3%$3.00-31.0%N/A$321.99MN/A0.00N/AGap DownOLMAOlema Pharmaceuticals2.514 of 5 stars$4.26-7.8%$24.50+475.1%-56.4%$316.11MN/A0.0070News CoveragePositive News Related Companies and Tools Related Companies TERN Competitors HUMA Competitors PRTA Competitors HRTX Competitors AMRN Competitors PRME Competitors SNDL Competitors AQST Competitors CTOR Competitors OLMA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IVVD) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invivyd, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Invivyd With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
